retatrutide mechanism retatrutide clinical trials 2024 2025 ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide Phase 3 Results 2026:

(2009) Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects, Growth Horm IGF Res, 19(6), pp

Do not stop the use of this medicine without consulting your doctor

The long-term side effects of tirzepatide are still not well-known

Use the Federal Poverty Level Calculator to calculate your households FPL percentage based on your income and household size

Obesity: Jastreboff et al., 2023 (NEJM) Jastreboff, Kaplan, Fras, and colleagues reported a phase 2, double-blind, randomized, placebo-controlled trial in the New England Journal of Medicine in 2023 [4]